Tivozanib
| CAS No. | 475108-18-0 |
|---|---|
| MDL No. | MFCD15146788 |
| MF | C22H19ClN4O5 |
| MW | 454.90 |
| InChI Key | SPMVMDHWKHCIDT-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Tivozanib is a 6,7-dimethoxyquinoline substituted with a 3-chloro-4-{[(5-methyl-1,2-oxazol-3-yl)carbamoyl]amino}phenoxy group at position 4. It is a potent and selective VEGF receptor tyrosine kinase inhibitor that was in clinical development for metastatic renal cell carcinoma. It functions as a VEGF receptor antagonist, antineoplastic agent, and apoptosis inducer. It is an aromatic ether, a member of isoxazoles, phenylureas, monochlorobenzenes, and quinolines.
| CAS No. | 475108-18-0 |
|---|---|
| Product Name | Tivozanib |
Biological Targets
PDGFRB·KIT·FLT1·FLT4·KDR
Associated Conditions
cholangiocarcinoma·fallopian tube cancer·renal cell adenocarcinoma·liver disease·glioblastoma multiforme·
* The information provided here is compiled from public sources and is for reference only.
